Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Becker

Showing results (251-260 of 274) with videos related to

Pageof 28
Sort By:
Nature Microbiology|March 26, 2024
Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogensRüdiger Groß, Hanna Reßin, Pascal von Maltitz, et al.
Journal of Virology|September 16, 2024
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive networkNina Hofmann, Marek Bartkuhn, Stephan Becker, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccinationAlina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
The New England Journal of Medicine|April 12, 2003
Identification of a novel coronavirus in patients with severe acute respiratory syndromeChristian Drosten, Stephan Günther, Wolfgang Preiser, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
Plos Medicine|October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trialSelidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
EMBO Molecular Medicine|January 1, 2015
Investigating the zoonotic origin of the West African Ebola epidemicAlmudena Marí Saéz, Sabrina Weiss, Kathrin Nowak, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 12, 2017
Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016Clara Lehmann, Matthias Kochanek, Diana Abdulla, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Pageof 28

Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
Nature Microbiology|March 26, 2024
Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogensRüdiger Groß, Hanna Reßin, Pascal von Maltitz, et al.
Journal of Virology|September 16, 2024
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive networkNina Hofmann, Marek Bartkuhn, Stephan Becker, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccinationAlina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
The New England Journal of Medicine|April 12, 2003
Identification of a novel coronavirus in patients with severe acute respiratory syndromeChristian Drosten, Stephan Günther, Wolfgang Preiser, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
Plos Medicine|October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trialSelidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
EMBO Molecular Medicine|January 1, 2015
Investigating the zoonotic origin of the West African Ebola epidemicAlmudena Marí Saéz, Sabrina Weiss, Kathrin Nowak, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 12, 2017
Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016Clara Lehmann, Matthias Kochanek, Diana Abdulla, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Pageof 28